Exatecan NEW

Exatecan

• Product Information

• Product No.：E068000

• English Name：Exatecan

• English Alias：(1S,9S)-1-amino-9-ethyl-5-fluoro-9-hydroxy-4-methyl-2,3,12,15-tetrahydrobenzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-10,13(1H,9H)-dione

• CAS No.：171335-80-1

• Molecular Formula：C₂₄H₂₂FN₃O₄

• Molecular Weight：435.45

• Advantages

• As a topoisomerase Ⅰ inhibitor, it has potential antitumor activity. It can interfere with DNA replication and transcription by inhibiting the function of topoisomerase Ⅰ, thereby suppressing tumor cell proliferation.

• The fluorine atom and polycyclic system in the structure may enhance the binding ability to the target and the metabolic stability of the drug.

• Applications

• Mainly used in the research and development of antitumor drugs, as a candidate compound or tool drug to explore its potential in cancer treatment.

• Can be used for the study of topoisomerase Ⅰ-related action mechanisms, providing a theoretical basis for the development of new anticancer drugs.

• Background Description

• Exatecan belongs to camptothecin derivatives, which exert antitumor effects by inhibiting topoisomerase Ⅰ. The structure of this compound is modified based on the camptothecin parent nucleus (such as introducing substituents like fluorine atoms and ethyl groups) to optimize efficacy, reduce toxicity, or improve pharmacokinetic properties. Its research background is closely related to the demand for tumor-targeted therapy, aiming to develop new anticancer drugs with high efficiency and low toxicity.

• Research Status

• Studies have shown that Exatecan has cytotoxicity against a variety of tumor cell lines (such as lung cancer and colorectal cancer), and its mechanism of action is clear. However, its in vivo pharmacokinetic properties (such as stability and metabolic pathways) and safety still need further optimization.

• Some studies focus on the synthesis and structure-activity relationship analysis of its derivatives to find analogs with higher activity and fewer side effects. At present, this compound may be in the preclinical research or early clinical trial stage and has not been widely used in clinical treatment.

WhatsAPP: +86 17320513646
E-mail: anna@molcoo.com

• 
  

NOTE！

We can also customize related analogues and modified peptides including HPLC, MS, 1H-NMR, MS, HPLC, IR, UV, COA, MSDS.
This product is intended for laboratory use only!

WhatsAPP: +86 17320513646
E-mail: anna@molcoo.com




NEW IN STOCK!


The Molcoo Laboratory added drug impurity reference standards, including Baricitinib, Piperazine, Benzylpenicillin, Tranilast and multiple N-Nitroso drug impurities! Now available for immediate delivery!